Common Contracts

2 similar Agreement and Plan of Merger contracts by Panbela Therapeutics, Inc.

AGREEMENT AND PLAN OF MERGER by and among PANBELA THERAPEUTICS, INC., CANARY MERGER HOLDINGS, INC., CANARY MERGER SUBSIDIARY I, INC., CANARY MERGER SUBSIDIARY II, INC., CANCER PREVENTION PHARMACEUTICALS, INC. and FORTIS ADVISORS LLC, as Stockholder...
Agreement and Plan of Merger • February 22nd, 2022 • Panbela Therapeutics, Inc. • Pharmaceutical preparations • Delaware

This Agreement and Plan of Merger (this “Agreement”), is entered into as of February 21, 2022, by and among Cancer Prevention Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Panbela Therapeutics, Inc., a Delaware corporation (“Parent”), Canary Merger Holdings, Inc., a Delaware corporation and direct wholly owned subsidiary of Parent (“HoldCo”), Canary Merger Subsidiary I, Inc., a Delaware corporation and a wholly-owned Subsidiary of HoldCo (“Merger Sub I”), Canary Merger Subsidiary II, Inc., a Delaware corporation and a wholly-owned Subsidiary of HoldCo (“Merger Sub II”, and together with Parent, HoldCo and Merger Sub I, the “Parent Entities”), and Fortis Advisors, LLC, a Delaware limited liability company, in its capacity as Stockholder Representative (“Stockholder Representative”). Capitalized terms used herein (including in the immediately preceding sentence) and not otherwise defined herein shall have the meanings set forth in Section 9.01 hereof.

AutoNDA by SimpleDocs
AGREEMENT AND PLAN OF MERGER by and among PANBELA THERAPEUTICS, INC., CANARY MERGER HOLDINGS, INC., CANARY MERGER SUBSIDIARY I, INC., CANARY MERGER SUBSIDIARY II, INC., CANCER PREVENTION PHARMACEUTICALS, INC. and FORTIS ADVISORS LLC, as Stockholder...
Agreement and Plan of Merger • February 22nd, 2022 • Panbela Therapeutics, Inc. • Pharmaceutical preparations • Delaware

This Agreement and Plan of Merger (this “Agreement”), is entered into as of February 21, 2022, by and among Cancer Prevention Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Panbela Therapeutics, Inc., a Delaware corporation (“Parent”), Canary Merger Holdings, Inc., a Delaware corporation and direct wholly owned subsidiary of Parent (“HoldCo”), Canary Merger Subsidiary I, Inc., a Delaware corporation and a wholly-owned Subsidiary of HoldCo (“Merger Sub I”), Canary Merger Subsidiary II, Inc., a Delaware corporation and a wholly-owned Subsidiary of HoldCo (“Merger Sub II”, and together with Parent, HoldCo and Merger Sub I, the “Parent Entities”), and Fortis Advisors, LLC, a Delaware limited liability company, in its capacity as Stockholder Representative (“Stockholder Representative”). Capitalized terms used herein (including in the immediately preceding sentence) and not otherwise defined herein shall have the meanings set forth in Section 9.01 hereof.

Time is Money Join Law Insider Premium to draft better contracts faster.